Everest Organics starts API production for Merck anti-COVID pill
![](/46/pdcnewsitem/11/47/02/HLN00CPO_Molnupiravir_784x590.jpg)
Manufacturer starts development of API for molnupiravir, which is set to become world’s first oral treatment against coronavirus
India’s Everest Organics has started manufacturing the active pharmaceutical ingredient for Merck & Co’s investigational antiviral pill, molnupiravir, to treat mild to moderate COVID-19, the API manufacturer said in a filing to the Bombay Stock Exchange.
“After the successful development and commercialization of various COVID-19 drugs, such as Oseltamivir, Remdesivir, Posaconazole, Everest Organics is on its path of expansion of this portfolio and hence has further developed an additional COVID-19 treatment API in that segment,” said Srikakarlapudi Sirisha, Chief Executive Officer, New Product Development at Everest Organics.
The company said in the filing that the drug was being developed at lab scale.
Earlier this month, Merck and partner Ridgeback Biotherapeutics announced that in a Phase 3 trial, molnupiravir reduced the risk of hospitalization and death by around 50% for patients with mild or moderate cases of COVID-19. The APl is administered orally and works by inhibiting the replication of the coronavirus inside the body.
The two companies have submitted an Emergency Use Application for the pill to the US Food and Drug Administration, which if approved would make it the world’s first oral antiviral treatment for COVID-19.
Everest Organics has an API facility in Hyderabad, India and manufactures and exports APIs to more than 40 countries as well as serving domestic demand.
![Everest Organics Ltd](https://www.cphi-online.com/th250934-comp250934.png)
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance